Steady-state energy balance in animal models of obesity and weight loss

Scandinavian Journal of Gastroenterology

Volumn 52, Issue 4, 2017, Pages 442-449

  Olsen, Magnus Kringstad ^a   Johannessen, Helene ^a   Cassie, Nikki ^b   Barrett, Perry ^b   Takeuchi, Koji ^c   Kulseng, Bård ^a,d   Chen, Duan ^a,d   Zhao, Chun Mei ^a  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b ROWETT RESEARCH INSTITUTE   (United Kingdom)

^c KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

^d TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

Eating behaviour; gastric bypass; high fat diet; mice; muscarinic acetylcholine M3 receptor knockout; rats

Indexed keywords

AGOUTI RELATED PROTEIN; FAT; LEPTIN RECEPTOR; MESSENGER RNA; MUSCARINIC M3 RECEPTOR; NEUROPEPTIDE Y; FAT INTAKE;

ANIMAL EXPERIMENT; ARTICLE; BODY COMPOSITION; BODY WEIGHT; CALORIC INTAKE; CONTROLLED STUDY; DIET INDUCED OBESITY; ENERGY BALANCE; ENERGY EXPENDITURE; FOOD INTAKE; GASTRIC BYPASS SURGERY; GENE EXPRESSION; GENE INACTIVATION; IN SITU HYBRIDIZATION; LABORATORY TEST; LIGHT DARK CYCLE; LIPID DIET; LUNG GAS EXCHANGE; MALE; MONITORING; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; SHAM PROCEDURE; STEADY STATE; WEIGHT REDUCTION; WILD TYPE MOUSE; ANIMAL; BRAIN; C57BL MOUSE; DISEASE MODEL; ENERGY METABOLISM; FAT INTAKE; FEMALE; GENETICS; KNOCKOUT MOUSE; METABOLISM; MOUSE MUTANT; OBESITY; PATHOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; BRAIN; DIETARY FATS; DISEASE MODELS, ANIMAL; ENERGY METABOLISM; FEMALE; GASTRIC BYPASS; IN SITU HYBRIDIZATION; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, OBESE; OBESITY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, MUSCARINIC M3; RNA, MESSENGER; WEIGHT LOSS;

EID: 85006856630     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.1080/00365521.2016.1267791     Document Type: Article

References (41)

1. WHO. Obesity:preventing and managing the global epidemic. Report of a WHO Consultation. Paper presented at:The World Health Organization; 1997 June 3–5; Geneva, Switzerland. Publication WHO/NUT/NCD/98.1.
2. Danaei G, Finucane MM, Lu Y, et al. Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating G. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980:systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet. 2011;378:31–40.
3. Burton BT, Foster WR., Health implications of obesity:an NIH Consensus Development Conference. J Am Diet Assoc. 1985;85:1117–1121.
4. Guh DP, Zhang W, Bansback N, et al. The incidence of co-morbidities related to obesity and overweight:a systematic review and meta-analysis. BMC Public Health 2009;9:88. doi:10.1186/1471-2458-9-88.
5. Tsai AG, Wadden TA., In the clinic:obesity. Ann Intern Med. 2013;159:ITC3-1-ITC3-15; quiz ITC3-6.
6. Colquitt J, Picot J, Loveman E, et al. Surgery for obesity. Cochrane Database Syst Rev. 2009:CD003641. doi:10.1002/14651858.CD003641.
7. Gloy VL, Briel M, Bhatt DL, et al. Bariatric surgery versus non-surgical treatment for obesity:a systematic review and meta-analysis of randomised controlled trials. BMJ 2013;22:f5934. doi:10.1136/bmj.f5934.
8. Carvajal R, Wadden TA, Tsai AG, et al. Managing obesity in primary care practice:a narrative review. Ann N Y Acad Sci. 2013;1281:191–206.
9. Yanovski SZ, Yanovski JA., Long-term drug treatment for obesity:a systematic and clinical review. JAMA 2014;311:74–86.
10. Rodgers RJ, Tschop MH, Wilding JP., Anti-obesity drugs:past, present and future. Dis Model Mech. 2012;5:621–626.
11. Arch JR., The discovery of drugs for obesity, the metabolic effects of leptin and variable receptor pharmacology:perspectives from beta3-adrenoceptor agonists. Naunyn Schmiedebergs Arch Pharmacol. 2008;378:225–240.
12. Mund RA, Frishman WH. Brown adipose tissue thermogenesis:β3-adrenoreceptors as a potential target for the treatment of obesity in humans. Cardiol Rev. 2013;21:265–269.
13. Manore MM, Brown K, Houtkooper L, et al. Energy balance at a crossroads:translating the science into action. Med Sci Sports Exerc. 2014;46:1466–1473.
14. Gautron L, Elmquist JK, Williams KW., Neural control of energy balance:translating circuits to therapies. Cell. 2015;161:133–145.
15. Hill JO, Wyatt HR, Peters JC., Energy balance and obesity. Circulation. 2012;126:126–132.
16. Hill JO., Understanding and addressing the epidemic of obesity:an energy balance perspective. Endocr Rev. 2006;27:750–761.
17. Furnes MW, Zhao CM, Chen D., Development of obesity is associated with increased calories per meal rather than per day. A study of high-fat diet-induced obesity in young rats. Obes Surg. 2009;19:1430–1438.
18. la Fleur SE, Luijendijk MC, van der Zwaal EM, et al. The snacking rat as model of human obesity:effects of a free-choice high-fat high-sugar diet on meal patterns. Int J Obes (Lond). 2014;38:643–649.
19. Archer ZA, Rayner DV, Duncan JS, et al. Introduction of a high-energy diet acutely up-regulates hypothalamic cocaine and amphetamine-regulated transcript, Mc4R and brown adipose tissue uncoupling protein-1 gene expression in male Sprague–Dawley rats. J Neuroendocrinol. 2005;17:10–17.
20. Archer ZA, Rayner DV, Mercer JG., Hypothalamic gene expression is altered in underweight but obese juvenile male Sprague–Dawley rats fed a high-energy diet. J Nutr. 2004;134:1369–1374.
21. Briggs DI, Enriori PJ, Lemus MB, et al. Diet-induced obesity causes ghrelin resistance in arcuate NPY/AgRP neurons. Endocrinology. 2010;151:4745–4755.
22. Archer ZA, Rayner DV, Barrett P, et al. Hypothalamic energy balance gene responses in the Sprague–Dawley rat to supplementation of high-energy diet with liquid ensure and subsequent transfer to chow. J Neuroendocrinol. 2005;17:711–719.
23. Furnes M, Tømmerås K, Arum C-J, et al. Gastric bypass surgery causes body weight loss without reducing food intake in rats. Obes Surg. 2008;18:415–422.
24. Furnes MW, Stenstrom B, Tommeras K, et al. Feeding behavior in rats subjected to gastrectomy or gastric bypass surgery. Eur Surg Res. 2008;40:279–288.
25. Kodama Y, Johannessen H, Furnes MW, et al. Mechanistic comparison between gastric bypass vs. duodenal switch with sleeve gastrectomy in rat models. PLoS One 2013;8:e72896. doi:10.1371/journal.pone.0072896.
26. Bueter M, Lowenstein C, Olbers T, et al. Gastric bypass increases energy expenditure in rats. Gastroenterology. 2010;138:1845–1853.
27. Bueter M, le Roux CW., Gastrointestinal hormones, energy balance and bariatric surgery. Int J Obes. 2011;35:S35–S39.
28. Xu Y, Ramos EJ, Middleton F, et al. Gene expression profiles post Roux-en-Y gastric bypass. Surgery. 2004;136:246–252.
29. Yamada M, Miyakawa T, Duttaroy A, et al. Mice lacking the M3 muscarinic acetylcholine receptor are hypophagic and lean. Nature. 2001;410:207–212.
30. Schwartz MW, Woods SC, Porte D, Jr, et al. Central nervous system control of food intake. Nature. 2000;404:661–671.
31. Gautam D, Gavrilova O, Jeon J, et al. Beneficial metabolic effects of M3 muscarinic acetylcholine receptor deficiency. Cell Metab. 2006;4:363–375.
32. Matsui M, Motomura D, Karasawa H, et al. Multiple functional defects in peripheral autonomic organs in mice lacking muscarinic acetylcholine receptor gene for the M3 subtype. Proc Natl Acad Sci U S A. 2000;97:9579–9584.
33. Ramos-Jimenez A, Hernandez-Torres RP, Torres-Duran PV, et al. The respiratory exchange ratio is associated with fitness indicators both in trained and untrained men:a possible application for people with reduced exercise tolerance. Clin Med Circ Respir Pulm Med. 2008;2:1–9.
34. Kindel T, Lomelin D, McBride C, et al. The time to weight-loss steady state after gastric bypass predicts weight-loss success. Obes Surg. 2016;26:327–331.
35. Luo N, Marcelin G, Liu SM, et al. Neuropeptide Y and agouti-related peptide mediate complementary functions of hyperphagia and reduced energy expenditure in leptin receptor deficiency. Endocrinology. 2011;152:883–889.
36. Maresca A, Supuran CT., Muscarinic acetylcholine receptors as therapeutic targets for obesity. Expert Opin Ther Targets. 2008;12:1167–1175.
37. Chugh PK, Sharma S., Recent advances in the pathophysiology and pharmacological treatment of obesity. J Clin Pharm Ther. 2012;37:525–535.
38. Amorim BS, Ueta CB, Freitas BC, et al. A TRbeta-selective agonist confers resistance to diet-induced obesity. J Endocrinol. 2009;203:291–299.
39. Hwang JH, Kim DW, Jo EJ, et al. Pharmacological stimulation of NADH oxidation ameliorates obesity and related phenotypes in mice. Diabetes. 2009;58:965–974.
40. Villicev CM, Freitas FR, Aoki MS, et al. Thyroid hormone receptor beta-specific agonist GC-1 increases energy expenditure and prevents fat-mass accumulation in rats. J Endocrinol. 2007;193:21–29.
41. Corp KGLS. Safety, Tolerability and Pharmacokinetic Study of MB12066 in Healthy Volunteers:ClinicalTrials.gov [Internet]. 2011. Available from:http://clinicaltrials.gov/ct2/show/record/NCT01444677?term=mb12066&rank =1.